Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation.
Cystic Fibrosis
airway
gut
microbiome
potentiator
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
19
03
2021
revised:
15
04
2021
accepted:
25
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Ivacaftor has been shown to restore the functionality of the S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology and micro-environment, resulting in a change of microbiota in these organs. The aim of the present study was to analyze the effects of ivacaftor on the microbial community composition of both airway and gut in subjects with CF carrying one S1251N mutation, using a 16S rRNA gene-based sequencing approach. In 16 subjects with CF, repetitive samples from airways and gut were collected just before, and 2 months after, and, for 8 patients, also 9 and 12 months after, start of ivacaftor. 16S rRNA based sequencing identified 344 operational taxonomical units (OTUs) in a total of 139 samples (35 nasopharyngeal, 39 oropharyngeal, 29 sputum, and 36 fecal samples). Ivacaftor significantly enhanced bacterial diversity and overall microbiota composition in the gut (
Identifiants
pubmed: 33925519
pii: jpm11050350
doi: 10.3390/jpm11050350
pmc: PMC8146888
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chief Scientist Office
ID : SCAF/16/03
Pays : United Kingdom
Références
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25
pubmed: 23590265
J Cyst Fibros. 2018 Jan;17(1):89-95
pubmed: 28711222
PLoS One. 2012;7(4):e36313
pubmed: 22558432
PLoS One. 2009 Oct 09;4(10):e7370
pubmed: 19816605
Pediatr Pulmonol. 2020 Dec;55(12):3381-3383
pubmed: 32910556
Ann Am Thorac Soc. 2020 Feb;17(2):212-220
pubmed: 31604026
Hum Pathol. 1976 May;7(3):297-307
pubmed: 773810
Am J Respir Crit Care Med. 2016 Mar 1;193(5):504-15
pubmed: 26492486
N Engl J Med. 2005 May 12;352(19):1992-2001
pubmed: 15888700
Annu Rev Med. 2007;58:157-70
pubmed: 17217330
PLoS One. 2014 Jul 11;9(7):e102045
pubmed: 25013895
Appl Environ Microbiol. 2011 Nov;77(22):8015-24
pubmed: 21926193
mBio. 2014 Mar 18;5(2):e00956-13
pubmed: 24643867
Lancet Respir Med. 2016 Jan;4(1):73-82
pubmed: 26700443
J Cyst Fibros. 2012 May;11(3):237-45
pubmed: 22293084
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30
pubmed: 19846789
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1104-1115
pubmed: 27135599
Sci Rep. 2016 May 04;6:24857
pubmed: 27143104
Vaccine. 2013 Dec 17;32(1):165-79
pubmed: 24331112
Arch Dis Child. 2018 Jan;103(1):68-70
pubmed: 27288428
EBioMedicine. 2016 Jul;9:336-345
pubmed: 27333043
J Cyst Fibros. 2018 Jan;17(1):50-56
pubmed: 29042177
Eur Respir J. 2017 Mar 29;49(3):
pubmed: 28356374
Nat Rev Genet. 2015 Jan;16(1):45-56
pubmed: 25404111
N Engl J Med. 2011 Nov 3;365(18):1663-72
pubmed: 22047557
mBio. 2012 Aug 21;3(4):
pubmed: 22911969
PLoS One. 2015 Apr 08;10(4):e0124124
pubmed: 25853698
Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84
pubmed: 24927234
Clin Infect Dis. 2015 Mar 1;60(5):703-12
pubmed: 25425629
J Clin Microbiol. 2003 Aug;41(8):3548-58
pubmed: 12904354
Dig Dis Sci. 2016 Jan;61(1):198-207
pubmed: 26250833